Prime time for prospective randomized trials of targeted therapies with validated targets in lung cancer: FDA perspective

被引：0
|
作者：
Malik, Shakun [1 ]
Justice, Robert [1 ]
Sridhara, Rajeshwari [1 ]
Waxman, Ian [1 ]
Pazdur, Richard [1 ]
机构：
[1] US FDA, CDER, Silver Spring, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S235 / S236
页数：2
相关论文
共 50 条
  • [21] No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Senti, Chiara
    Bottini, Alberto
    Generali, Daniele
    CLINICAL LUNG CANCER, 2016, 17 (05) : 334 - 340
  • [22] Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer
    Rybinski, Brad
    Hosgood, H. Dean
    Wiener, Sara L.
    Weiser, Daniel A.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study
    Hsu, Jason C.
    Wei, Chen-Fang
    Yang, Szu-Chun
    Lin, Peng-Chan
    Lee, Yang-Cheng
    Lu, Christine Y.
    BMJ OPEN, 2020, 10 (05):
  • [24] Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
    Berge, Eamon M.
    Doebele, Robert C.
    SEMINARS IN ONCOLOGY, 2014, 41 (01) : 110 - 125
  • [25] A retrospective look: Industry partnership and transparency in phase III randomized clinical trials of breast cancer targeted therapies across two decades
    Ruan, Qiao
    Mann-Grewal, Amandeep Kaur
    Johnson, Caitlin Ruth
    Behler, Caroline
    Kapp, Daniel Stuart
    Chan, John K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Targeted therapies for non-small-cell lung cancer: Biology, rationale, and preclinical results from a radiation oncology perspective
    Raben, D
    Helfrich, B
    Bunn, PA
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02): : 27 - 38
  • [27] Characteristics and study eligibility of British lung cancer patients for clinical trials evaluating targeted therapies (TTS) or immune checkpoint inhibitors (ICIS)
    van Veelen, Ard
    Abtahi, Shahab
    Souverein, Patrick
    Driessen, Johanna H. M.
    Klungel, Olaf H.
    Dingemans, Anne-Marie
    van Geel, Robin
    de Vries, Frank
    Croes, Sander
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 46 - 46
  • [28] Comparative Efficacy of Targeted Therapies in Patients with Non-Small Cell Lung Cancer: A Network Meta-Analysis of Clinical Trials
    Hoang, Tung
    Myung, Seung-Kwon
    Thu Thi Pham
    Kim, Jeongseon
    Ju, Woong
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [29] Non-Small-Cell Lung Cancer: New Rare Targets-New Targeted Therapies-State of The Art and Future Directions
    Stencel, Katarzyna
    Chmielewska, Izabela
    Milanowski, Janusz
    Ramlau, Rodryg
    CANCERS, 2021, 13 (08)
  • [30] Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials
    LeVasseur, Nathalie
    Clemons, Mark
    Hutton, Brian
    Shorr, Risa
    Jacobs, Carmel
    CANCER TREATMENT REVIEWS, 2016, 50 : 183 - 193
12345